PacBio Announces Second Quarter 2026 Financial Results
Rhea-AI Summary
PacBio (NASDAQ:PACB) reported Q2 2026 revenue of $39.0 million, slightly below $39.8 million in Q2 2025, driven by consumables growth and new Revio and Vega placements amid the global commercial rollout of its SPRQ-Nx chemistry for whole genome sequencing at a $345 list price per genome.
Consumable revenue was $20.1 million (up from $18.9 million), instrument revenue $12.8 million (down from $14.2 million), and service and other revenue $6.1 million (down from $6.7 million). GAAP gross profit was $12.6 million with a 32% margin; non-GAAP gross profit was $13.9 million with a 36% margin, both below prior-year levels.
GAAP operating expenses were $57.2 million, GAAP net loss $44.7 million (non-GAAP net loss $41.9 million), and GAAP net loss per share remained $0.14. PacBio ended the quarter with $236.9 million in cash, cash equivalents, and investments and expects full-year 2026 revenue of $155–$165 million. The company also implemented restructuring actions and highlighted several key scientific publications and population-scale program milestones.
Positive
- Consumable revenue growth to $20.1M from $18.9M YoY
- Revio system placements increased to 20 from 15 YoY
- Full-year 2026 revenue guidance set at $155–$165M
- Cash, cash equivalents, and investments of $236.9M at June 30, 2026
Negative
- Total revenue declined to $39.0M from $39.8M YoY
- GAAP gross margin fell to 32% from 37% YoY
- Non-GAAP gross margin declined to 36% from 38% YoY
- GAAP net loss widened to $44.7M from $41.9M YoY
- Vega system placements decreased to 26 from 38 YoY
- Annualized Revio pull-through decreased to ~$202,000 from ~$219,000 YoY
- Cash, cash equivalents, and investments decreased to $236.9M from $314.7M YoY
News Explained
The August 5 release reports PacBio’s second-quarter results for the quarter ended
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | 1Q26 earnings report | Negative | -14.6% | Quarterly results included $37.2M revenue and reduced full-year guidance. |
| Feb 12 | 4Q25 earnings report | Positive | -7.1% | Margin improvement, cash resources, and short-read asset sale accompanied a negative reaction. |
| Nov 05 | 3Q25 earnings report | Positive | -7.0% | Improved non-GAAP margin and narrowed non-GAAP loss accompanied a negative reaction. |
| Aug 07 | 2Q25 earnings report | Positive | +7.1% | Revenue increased year over year while the reported loss narrowed substantially. |
| May 08 | 1Q25 earnings report | Negative | -6.7% | Revenue declined and GAAP net loss widened substantially year over year. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-matched earnings events produced predominantly negative 24-hour reactions, with an average move of -5.64%.
Key Terms
gaap financial
non-gaap financial
convertible senior notes financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026.
Recent Business Highlights
- Total revenue of
$39.0 million was driven by growing consumables and new Revio and Vega placements as the Company commenced its full rollout of SPRQ-Nx chemistry. Instrument revenue consisted of both single-system and multi-system orders, including an order for several Revio systems from a new population-scale customer - Commenced global commercial rollout of SPRQ-Nx, delivering whole genome sequencing at
$345 USD list price per genome with enhanced methylation detection and DeepConsensus, an AI-powered consensus algorithm co-developed with Google - Commenced sequencing and sample delivery for Basecamp Research, a frontier AI lab for therapeutic design, marking a significant operational milestone for PacBio's largest population-scale program to date
- Published in a landmark New England Journal of Medicine study, "Clinical Long-Read Genome Sequencing for Rare-Disease Diagnostics." The publication demonstrates that HiFi long-read sequencing is a clinically effective first-tier diagnostic test that improves diagnostic yield while simplifying the laboratory workflow, reducing turnaround time, and enhancing the overall economics of rare disease diagnostics
- Published in a Nature Genetics article, “Near-perfect genome sequencing in medical genetics.” The publication highlights long-read sequencing as a pillar of near-perfect genome sequencing (NPGS), alongside diploid genome assembly, pangenome references, and AI-driven variant interpretation
- Contributed to a published preprint from the HiFi Solves Sub-fertility Consortium in Asia Pacific. The preprint demonstrates that PacBio HiFi whole genome sequencing can provide a more complete view of reproductive genetics in one workflow
- Implemented restructuring actions primarily to streamline marketing and R&D organizations, strengthen the go-to-market commercial organization, and drive greater cost discipline going forward
Second quarter results:
| Q2 2026 | Q2 2025 | |
| Revenue (in millions) | ||
| Consumable revenue (in millions) | ||
| Instrument revenue (in millions) | ||
| Service and other revenue (in millions) | ||
| Revio™system placements | 20 | 15 |
| Vega™ system placements | 26 | 38 |
| Annualized Revio pull-through per system | ~ | ~ |
| Ending cash, cash equivalents, and investments (in millions) | ||
Gross profit and margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP measures at the end of this release.
GAAP gross profit for the second quarter of 2026 was
GAAP operating expenses totaled
GAAP net loss for the second quarter of 2026 was
GAAP net loss per share for the second quarter of 2026 was
2026 Financial Outlook
PacBio expects revenue for the full year 2026 to be in the range of
Quarterly Conference Call Information
Management will host a quarterly conference call today at 4:30 p.m. Eastern Time to review financial results for the second quarter ended June 30, 2026. Investors can access the call by dialing 1-888-349-0136 (or 1-412-317-0459 for international callers) and requesting to join the “PacBio Q2 Earnings Call". The call will be webcast live and available for replay at PacBio's website at https://investor.pacificbiosciences.com.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which primarily consist of our HiFi long-read sequencing systems, address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Statement regarding use of non‐GAAP financial measures
PacBio reports non‐GAAP results for basic net income (loss) per share, net income (loss), gross margins, gross profit (loss) and operating expenses in addition to, and not as a substitute for, or because it believes that such information is superior to, financial measures calculated in accordance with GAAP. PacBio believes that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of PacBio’s non-GAAP financial measures as tools for comparison.
PacBio's financial measures under GAAP include substantial charges that are listed in the itemized reconciliations between GAAP and non‐GAAP financial measures included in this press release. PacBio excludes recurring charges from its non-GAAP financial statements, including amortization of acquired intangible assets and changes in fair value of contingent consideration, and further excludes infrequent and limited charges including impairment charges, restructuring-related expenses for discrete restructuring events, settlement charges, disposition of short-read assets, benefits from income taxes and other adjustments and rounding differences.
Management has excluded the effects of these items in non‐GAAP measures to assist investors in analyzing and assessing past and future operating performance. In addition, management uses non-GAAP measures to compare PacBio’s performance relative to forecasts and strategic plans and to benchmark its performance externally against competitors.
PacBio encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business. A reconciliation of PacBio’s non-GAAP financial measures to their most directly comparable financial measure stated in accordance with GAAP has been provided in the financial statement tables included in this press release. PacBio is unable to reconcile future-looking non-GAAP guidance without unreasonable effort because certain items that impact this measure are out of PacBio's control and/or cannot be reasonably predicted at this time.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, statements relating to PacBio’s initiatives as well as the expected financial impact and timing of these plans and initiatives, including PacBio's expectations regarding long-read sequencing and SPRQ-Nx; PacBio's expectations regarding its restructuring efforts; PacBio’s financial guidance and expectations for future periods; new and continued reception of PacBio’s products and their expansion into new or existing markets; and the availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies. Reported results and orders for any instrument system should not be considered an indication of future performance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, but not limited to, challenges inherent in developing, manufacturing, launching, marketing and selling new products, and achieving anticipated new sales; potential cancellation of existing instrument orders; assumptions, risks and uncertainties related to the ability to attract new customers and retain and grow sales from existing customers; risks related to PacBio's ability to successfully execute and realize the benefits of acquisitions; the impact of new, increased or enhanced tariffs and export restrictions; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; high costs of computer memory components; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; potential product performance and quality issues and potential delays in development timelines; the possible loss of key employees, customers, or suppliers; customers and prospective customers curtailing or suspending activities using PacBio's products; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; risks associated with international operations; and other risks associated with general macroeconomic conditions and global economic or political instability, including war and other international conflicts, such as the conflicts in the Middle East. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
The unaudited condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in PacBio's Quarterly Report on Form 10-Q when filed with the Securities and Exchange Commission.
Contacts
Investors:
ir@pacb.com
Media:
pr@pacb.com
| Pacific Biosciences of California, Inc. Unaudited Condensed Consolidated Statements of Operations | |||||||||||
| Three Months Ended | |||||||||||
| (in thousands, except per share amounts) | June 30, 2026 | March 31, 2026 | June 30, 2025 | ||||||||
| Revenue: | |||||||||||
| Product revenue | $ | 32,950 | $ | 31,534 | $ | 33,083 | |||||
| Service and other revenue | 6,057 | 5,644 | 6,683 | ||||||||
| Total revenue | 39,007 | 37,178 | 39,766 | ||||||||
| Cost of Revenue: | |||||||||||
| Cost of product revenue (1) (2) (3) | 20,944 | 19,972 | 20,022 | ||||||||
| Cost of service and other revenue | 5,242 | 4,182 | 4,853 | ||||||||
| Amortization of acquired intangible assets | 183 | 183 | 183 | ||||||||
| Loss on purchase commitment (1) | — | — | 24 | ||||||||
| Total cost of revenue | 26,369 | 24,337 | 25,082 | ||||||||
| Gross profit | 12,638 | 12,841 | 14,684 | ||||||||
| Operating Expense: | |||||||||||
| Research and development | 23,022 | 19,608 | 22,529 | ||||||||
| Sales, general and administrative (1) (2) | 33,393 | 31,153 | 36,175 | ||||||||
| Settlement charges (2) | — | 15,400 | — | ||||||||
| Gain on disposal of assets (3) | — | (45,796 | ) | — | |||||||
| Amortization of acquired intangible assets | 833 | 833 | 833 | ||||||||
| Total operating expense | 57,248 | 21,198 | 59,537 | ||||||||
| Operating loss | (44,610 | ) | (8,357 | ) | (44,853 | ) | |||||
| Interest expense (4) | (2,110 | ) | (1,740 | ) | (1,738 | ) | |||||
| Other income, net | 2,037 | 2,006 | 4,696 | ||||||||
| Loss before income taxes | (44,683 | ) | (8,091 | ) | (41,895 | ) | |||||
| Income tax provision | 58 | 184 | 35 | ||||||||
| Net loss | $ | (44,741 | ) | $ | (8,275 | ) | $ | (41,930 | ) | ||
| Net loss per share: | |||||||||||
| Basic | $ | (0.14 | ) | $ | (0.03 | ) | $ | (0.14 | ) | ||
| Diluted | $ | (0.14 | ) | $ | (0.03 | ) | $ | (0.14 | ) | ||
| Weighted average shares outstanding used in calculating net loss per share: | |||||||||||
| Basic | 310,405 | 305,819 | 300,162 | ||||||||
| Diluted | 310,405 | 305,819 | 300,162 | ||||||||
(1) Balances for the three months ended June 30, 2025 include restructuring costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts.
(2) Balances for the three months ended June 30, 2026 and March 31, 2026 include litigation settlement charges and related legal fees in connection with the agreement entered into with Personal Genomics of Taiwan, Inc. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts.
(3) Balances for the three months ended June 30, 2026 and March 31, 2026 include amounts related to the disposition of short-read assets, including the gain on the sale of certain assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies, and related non-recurring customer transition costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts.
(4) Balance for the three months ended June 30, 2026 includes interest expense related to the Personal Genomics of Taiwan, Inc. settlement liability.
| Pacific Biosciences of California, Inc. Unaudited Condensed Consolidated Statements of Operations | |||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||
| (in thousands, except per share amounts) | June 30, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | |||||||||||
| Revenue: | |||||||||||||||
| Product revenue | $ | 32,950 | $ | 33,083 | $ | 64,484 | $ | 64,196 | |||||||
| Service and other revenue | 6,057 | 6,683 | 11,701 | 12,723 | |||||||||||
| Total revenue | 39,007 | 39,766 | 76,185 | 76,919 | |||||||||||
| Cost of Revenue: | |||||||||||||||
| Cost of product revenue (1) (3) (4) | 20,944 | 20,022 | 40,916 | 46,355 | |||||||||||
| Cost of service and other revenue | 5,242 | 4,853 | 9,424 | 8,631 | |||||||||||
| Amortization of acquired intangible assets | 183 | 183 | 366 | 4,528 | |||||||||||
| Loss on purchase commitment (1) | — | 24 | — | 4,092 | |||||||||||
| Total cost of revenue | 26,369 | 25,082 | 50,706 | 63,606 | |||||||||||
| Gross profit | 12,638 | 14,684 | 25,479 | 13,313 | |||||||||||
| Operating Expense: | |||||||||||||||
| Research and development (1) | 23,022 | 22,529 | 42,630 | 51,582 | |||||||||||
| Sales, general and administrative (1) (3) | 33,393 | 36,175 | 64,546 | 76,343 | |||||||||||
| Impairment charges (2) | — | — | — | 15,000 | |||||||||||
| Settlement charges (3) | — | — | 15,400 | — | |||||||||||
| Gain on disposal of assets (4) | — | — | (45,796 | ) | — | ||||||||||
| Amortization of acquired intangible assets (5) | 833 | 833 | 1,666 | 362,875 | |||||||||||
| Change in fair value of contingent consideration (6) | — | — | — | (18,700 | ) | ||||||||||
| Total operating expense | 57,248 | 59,537 | 78,446 | 487,100 | |||||||||||
| Operating loss | (44,610 | ) | (44,853 | ) | (52,967 | ) | (473,787 | ) | |||||||
| Interest expense | (2,110 | ) | (1,738 | ) | (3,850 | ) | (3,475 | ) | |||||||
| Other income, net | 2,037 | 4,696 | 4,043 | 8,990 | |||||||||||
| Loss before income taxes | (44,683 | ) | (41,895 | ) | (52,774 | ) | (468,272 | ) | |||||||
| Income tax provision | 58 | 35 | 242 | (267 | ) | ||||||||||
| Net loss | $ | (44,741 | ) | $ | (41,930 | ) | $ | (53,016 | ) | $ | (468,005 | ) | |||
| Net loss per share: | |||||||||||||||
| Basic | $ | (0.14 | ) | $ | (0.14 | ) | $ | (0.17 | ) | $ | (1.57 | ) | |||
| Diluted | $ | (0.14 | ) | $ | (0.14 | ) | $ | (0.17 | ) | $ | (1.57 | ) | |||
| Weighted average shares outstanding used in calculating net loss per share: | |||||||||||||||
| Basic | 310,405 | 300,162 | 308,250 | 298,519 | |||||||||||
| Diluted | 310,405 | 300,162 | 308,250 | 298,519 | |||||||||||
(1) Balances for the three and six months ended June 30, 2025 include restructuring costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts.
(2) In-process research and development ("IPR&D") impairment charge during the six months ended June 30, 2025 was driven primarily by macroeconomic factors and restructuring initiatives, including the focus on long-read innovation, resulting in changes to the timing and amounts of cash flows.
(3) Balances for the three and six months ended June 30, 2026 include litigation settlement charges and related legal fees in connection with the agreement entered into with Personal Genomics of Taiwan, Inc. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts.
(4) Balances for the three and six months ended June 30, 2026 include amounts related to the disposition of short-read assets, including the gain on the sale of certain assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies, and related non-recurring customer transition costs. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts.
(5) Balance for the six months ended June 30, 2025 includes accelerated amortization of acquired intangible assets related to restructuring initiatives. Refer to the Reconciliation of Non-GAAP Financial Measures table below for additional information on such costs and related amounts.
(6) Change in fair value of contingent consideration during the six months ended June 30, 2025 was due to fair value adjustments of milestone payments payable upon the achievement of a milestone event.
| Pacific Biosciences of California, Inc. Unaudited Condensed Consolidated Balance Sheets | ||||||||
| (in thousands) | June 30, 2026 | December 31, 2025 | ||||||
| Assets | ||||||||
| Cash and investments | $ | 236,873 | $ | 279,506 | ||||
| Accounts receivable, net | 31,104 | 35,448 | ||||||
| Inventory, net | 61,084 | 49,285 | ||||||
| Prepaid expenses and other current assets | 9,545 | 10,793 | ||||||
| Property and equipment, net | 26,972 | 24,146 | ||||||
| Operating lease right-of-use assets, net | 40,331 | 41,695 | ||||||
| Restricted cash | 1,604 | 1,552 | ||||||
| Intangible assets, net | 13,084 | 15,124 | ||||||
| Goodwill | 317,761 | 317,761 | ||||||
| Other long-term assets | 13,492 | 8,773 | ||||||
| Total Assets | $ | 751,850 | $ | 784,083 | ||||
| Liabilities and Stockholders' (Deficit) Equity | ||||||||
| Accounts payable | $ | 19,224 | $ | 20,770 | ||||
| Accrued expenses | 30,322 | 33,646 | ||||||
| Deferred revenue | 19,442 | 19,865 | ||||||
| Operating lease liabilities | 61,795 | 57,040 | ||||||
| Convertible senior notes, net | 644,332 | 645,382 | ||||||
| Other liabilities | 9,948 | 2,031 | ||||||
| Stockholders' (deficit) equity | (33,213 | ) | 5,349 | |||||
| Total Liabilities and Stockholders' (Deficit) Equity | $ | 751,850 | $ | 784,083 | ||||
| Pacific Biosciences of California, Inc. Reconciliation of Non-GAAP Financial Measures | ||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||
| (in thousands, except per share amounts) | June 30, 2026 | March 31, 2026 | June 30, 2025 | June 30, 2026 | June 30, 2025 | |||||||||||||||
| GAAP net loss | $ | (44,741 | ) | $ | (8,275 | ) | $ | (41,930 | ) | $ | (53,016 | ) | $ | (468,005 | ) | |||||
| Change in fair value of contingent consideration (1) | — | — | — | — | (18,700 | ) | ||||||||||||||
| Settlement charges (2) | 284 | 16,804 | — | 17,088 | — | |||||||||||||||
| Amortization of acquired intangible assets | 1,016 | 1,016 | 1,016 | 2,032 | 8,144 | |||||||||||||||
| Amortization of patent license (3) | 516 | — | — | 516 | — | |||||||||||||||
| Disposition of short-read assets (4) | 611 | (45,490 | ) | — | (44,879 | ) | — | |||||||||||||
| Interest expense (5) | 369 | — | — | 369 | — | |||||||||||||||
| Income tax benefit (6) | — | — | — | — | (546 | ) | ||||||||||||||
| Restructuring (7) | — | — | 963 | — | 394,751 | |||||||||||||||
| Non-GAAP net loss | $ | (41,945 | ) | $ | (35,945 | ) | $ | (39,951 | ) | $ | (77,890 | ) | $ | (84,356 | ) | |||||
| GAAP basic net loss per share | $ | (0.14 | ) | $ | (0.03 | ) | $ | (0.14 | ) | $ | (0.17 | ) | $ | (1.57 | ) | |||||
| Change in fair value of contingent consideration (1) | — | — | — | — | (0.06 | ) | ||||||||||||||
| Settlement charges (2) | — | 0.05 | — | 0.06 | — | |||||||||||||||
| Amortization of acquired intangible assets | — | — | — | 0.01 | 0.03 | |||||||||||||||
| Disposition of short-read assets (4) | — | (0.15 | ) | — | (0.15 | ) | — | |||||||||||||
| Restructuring (7) | — | — | — | — | 1.32 | |||||||||||||||
| Other adjustments and rounding differences | — | 0.01 | 0.01 | — | — | |||||||||||||||
| Non-GAAP basic net loss per share | $ | (0.14 | ) | $ | (0.12 | ) | $ | (0.13 | ) | $ | (0.25 | ) | $ | (0.28 | ) | |||||
| GAAP gross profit | $ | 12,638 | $ | 12,841 | $ | 14,684 | $ | 25,479 | $ | 13,313 | ||||||||||
| Settlement charges (2) | — | 500 | — | 500 | — | |||||||||||||||
| Amortization of acquired intangible assets | 183 | 183 | 183 | 366 | 4,528 | |||||||||||||||
| Amortization of patent license (3) | 516 | — | — | 516 | — | |||||||||||||||
| Disposition of short-read assets (4) | 611 | 306 | — | 917 | — | |||||||||||||||
| Restructuring (7) | — | — | 348 | — | 12,375 | |||||||||||||||
| Non-GAAP gross profit | $ | 13,948 | $ | 13,830 | $ | 15,215 | $ | 27,778 | $ | 30,216 | ||||||||||
| GAAP gross profit % | 32 | % | 35 | % | 37 | % | 33 | % | 17 | % | ||||||||||
| Non-GAAP gross profit % | 36 | % | 37 | % | 38 | % | 36 | % | 39 | % | ||||||||||
| GAAP total operating expense | $ | 57,248 | $ | 21,198 | $ | 59,537 | $ | 78,446 | $ | 487,100 | ||||||||||
| Change in fair value of contingent consideration (1) | — | — | — | — | 18,700 | |||||||||||||||
| Settlement charges (2) | (284 | ) | (16,304 | ) | — | (16,588 | ) | — | ||||||||||||
| Amortization of acquired intangible assets | (833 | ) | (833 | ) | (833 | ) | (1,666 | ) | (3,616 | ) | ||||||||||
| Disposition of short-read assets (4) | — | 45,796 | — | 45,796 | — | |||||||||||||||
| Restructuring (7) | — | — | (615 | ) | — | (382,376 | ) | |||||||||||||
| Non-GAAP total operating expense | $ | 56,131 | $ | 49,857 | $ | 58,089 | $ | 105,988 | $ | 119,808 | ||||||||||
(1) Change in fair value of contingent consideration during the six months ended June 30, 2025 was due to fair value adjustments of milestone payments payable upon the achievement of a milestone event.
(2) Balances for the three months ended June 30, 2026 and March 31, 2026 and the six months ended June 30, 2026 include litigation settlement charges and related legal fees in connection with the agreement entered into with Personal Genomics of Taiwan, Inc.
(3) Balances for the three and six months ended June 30, 2026 include amortization of a patent license acquired in connection with the agreement entered into with Personal Genomics of Taiwan, Inc.
(4) Balances for the three months ended June 30, 2026 and March 31, 2026 and the six months ended June 30, 2026 include amounts related to the disposition of short-read assets, including the gain on the sale of certain assets related to our short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies, and related non-recurring customer transition costs.
(5) Interest expense for the three and six months ended June 30, 2026 is related to the liability incurred in connection with the agreement entered into with Personal Genomics of Taiwan, Inc.
(6) A deferred income tax benefit during the six months ended June 30, 2025 is primarily related to the change in the deferred tax liability balance resulting from the accelerated amortization of acquired intangible assets and IPR&D impairment.
(7) Restructuring-related costs incurred in connection with the 2025 plan during the three and six months ended June 30, 2025 consist primarily of costs included in cost of revenue related to excess inventory and purchase commitment losses, as well as costs included in operating expenses related to employee separation, accelerated depreciation, IPR&D impairment, and accelerated amortization of acquired intangibles.
